{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"221"},{"groupId":"OG001","value":"225"}],"units":"Participants"}],"description":"Part B: Number of Participants With Anti-Ramucirumab Antibodies.","groups":[{"description":"Part B: 10 mg/kg ramucirumab administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met.","id":"OG000","title":"Part B: Ramucirumab+ Erlotinib"},{"description":"Part B: Placebo administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met.","id":"OG001","title":"Part B: Placebo+ Erlotinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants who received at least one dose of study drug. Per protocol, Part A did not evaluate Anti-Ramucirumab Antibodies .","reportingStatus":"POSTED","timeFrame":"Cycle 1 Predose through Follow-up (Up To 37 Months)","title":"Part B: Number of Participants With Anti-Ramucirumab Antibodies","type":"SECONDARY","unitOfMeasure":"Participants"}